<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743351</url>
  </required_header>
  <id_info>
    <org_study_id>PT-001</org_study_id>
    <nct_id>NCT02743351</nct_id>
  </id_info>
  <brief_title>Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies</brief_title>
  <official_title>A Phase 1 Non-randomized/2 Randomized Study of ProTmuneâ„¢ (ex Vivo Programmed Mobilized Peripheral Blood Cells) for Allogeneic Hematopoietic Cell Transplantation in Adult Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, Non-randomized, Open-label/Phase 2 Randomized, Blinded Study of
      ProTmune (ex vivo programmed mobilized peripheral blood cells) Versus Non-programmed
      mobilized peripheral blood cells for Allogeneic Hematopoietic Cell Transplantation (HCT) in
      Adult Subjects Aged 18 to 70 years with Hematologic Malignancies. A maximum of 70 total
      eligible subjects will be enrolled and treated in the trial at approximately 15-20 centers in
      the US and EU.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment related AEs as assessed by CTCAE grading scale v.4.0</measure>
    <time_frame>by Day 365</time_frame>
    <description>Assessments include vital signs collection, physical examination findings, clinical laboratory assessments and electrocardiographic data through a 12-lead ECG</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients that experience Grade B-D acute Graft vs Host Disease (aGvHD)</measure>
    <time_frame>by Day 100</time_frame>
    <description>GvHD assessments of skin, liver and gastrointestinal involvement will be required to calculate the incidence of Grades B through D (CIBMTR) aGvHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>For CMV positive subjects, incidence of subjects with CMV viremia or who have initiated anti-viral therapy for CMV</measure>
    <time_frame>by Day 100</time_frame>
    <description>Central laboratory testing for CMV viremia (viral load &gt;/= 1000 IU/mL) or initiation of therapy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>ProTmune</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProTmune</intervention_name>
    <description>Ex-vivo, programmed mobilized peripheral blood (mPB) cells</description>
    <arm_group_label>ProTmune</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control Arm</intervention_name>
    <description>Untreated mobilized peripheral blood (mPB) cells</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male and female patients aged 18 to 70 years, inclusive;

          2. Patients must have a hematologic malignancy for which allogeneic hematopoietic
             peripheral blood cell transplantation is deemed clinically appropriate.

             Eligible diseases and stages include the following:

               1. Acute myeloid leukemia

               2. Acute lymphoblastic leukemia, including T lymphoblastic lymphoma with a history
                  of marrow involvement

               3. Myelodysplatic Syndrome

               4. Chronic Myelogenous leukemia

          3. Availability of a suitable 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated mPB donor;

          4. mBP donor collection that meets protocol specifications;

          5. Adequate performance status, defined as Karnofsky score greater than 70%;

          6. For female patients of childbearing potential, all of the following criteria must be
             met:

               -  They are not pregnant (i.e., female patients must have a negative serum pregnancy
                  test at screening);

               -  They are not breastfeeding;

               -  They do not plan to become pregnant during the study; and

               -  They are using an effective method of contraception from screening to the end of
                  the study, unless their sexual partner is surgically sterile

          7. For male patients, agreement to use condoms with spermicide during sexual intercourse
             from screening to the end of study; and

          8. Willingness and ability to sign an IRB/IEC approved ICF before performance of any
             study specific procedures or tests and to comply with protocol visits, and study
             procedures.

        Key Exclusion Criteria:

          1. Phase 1 only: known bone marrow fibrosis; Phase 2 only: Bone marrow fibrosis grade 2
             or greater;

          2. Positive serology for human immunodeficiency virus (HIV) or human T-cell lymphotropic
             virus (HTLV) at any time prior to enrollment;

          3. Currently uncontrolled bacterial, viral, or fungal infection (progression of clinical
             symptoms despite therapy);

          4. Prior autologous or allogeneic HCT;

          5. Active malignancy, other than the one for which the allogeneic mPB transplant is being
             performed, within 12 months of enrollment, excluding superficial basal cell and
             carcinoma in situ cervical cancer;

          6. Pulmonary disease, renal dysfunction, hepatic disease, cardiac disease, neurologic
             disease;

          7. Participation in another clinical trial involving an investigational product within 30
             days prior to screening; or

          8. Any condition or therapy, which, in the opinion of the Investigator, might pose a risk
             to the patient or make participation in the study not in the best interest of the
             patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris Storgard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica Diaz</last_name>
    <email>monica.diaz@fatetherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tiffany Hill</last_name>
      <phone>205-996-8023</phone>
      <email>tiffanydhill@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ayman Saad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Golnaz Namdar</last_name>
      <phone>626-218-0061</phone>
      <email>gnamdar@coh.org</email>
    </contact>
    <investigator>
      <last_name>Chatchada Karanes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD) Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Padilla</last_name>
      <phone>858-822-1921</phone>
      <email>MLP002@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Dimitrios Tzachanis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Schroeder</last_name>
      <phone>773-834-0982</phone>
      <email>lschroed@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Bishop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplant</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie R Coleman, RN BSN</last_name>
      <phone>317-528-5500</phone>
      <email>melanie.coleman@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>John R Edwards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corey Cutler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Ventimiglia</last_name>
      <phone>313-576-9271</phone>
      <email>ventimim@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Abhinav Deol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Whitney Reid</last_name>
      <email>whr2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Koen Van Besien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Clary</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>27124</phone_ext>
      <email>Nicole.clary1@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Essell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Dibb</last_name>
      <phone>503-494-2166</phone>
      <email>dibbw@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Maziarz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Cox</last_name>
      <phone>615-524-4174</phone>
      <email>amber.cox@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Carlos Bachier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jodell McCracken</last_name>
      <phone>210-575-4281</phone>
      <email>Jodell.mccracken@MHShealth.com</email>
    </contact>
    <investigator>
      <last_name>Cesar Freytes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute (University of Utah)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Carpenter</last_name>
      <phone>801-587-4756</phone>
      <email>Lindsay.Carpenter@hci.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Couriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Candler</last_name>
      <phone>804-828-4732</phone>
      <email>kcandler@vcu.edu</email>
    </contact>
    <investigator>
      <last_name>John McCarty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Transplants</keyword>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <keyword>HSCT</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>CML</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

